bioRxiv Science⌕ Search

Biology subjects

Maschietto, F.

Publications and source records attributed to Maschietto, F..

3 recordsLinked to original sources

Rewiring V-type and K-type enzyme allostery through subunit interface mutations

Allosteric regulation in the heterodimeric enzyme IGPS depends on long-range communication between the effector-binding HisF subunit and the catalytic HisH subunit. This signaling occurs through a densely packed interdomain interface enriched in conserved noncovalent contacts. Here, we use targeted interface mutations to determine how specific interfacial contacts tune the structural and dynamic features that govern allosteric control. The hK181A variant, which disrupts a critical salt bridge with fD98, converts IGPS into a constitutively more active enzyme, increasing basal glutaminase activity and substrate affinity. By contrast, hR18A, which disrupts a secondary salt bridge with fE71, weakens effector-induced activation, revealing functional asymmetry among interfacial interactions. NMR chemical shift perturbation and CPMG relaxation dispersion experiments show that hK181A remodels millisecond-timescale dynamics throughout HisF, consistent with molecular dynamics simulations indicating enhanced sampling of catalytically competent conformations. Network traffic analysis of correlated communication pathways, combined with energetic analysis, further shows that enthalpic and entropic contributions are redistributed to rewire long-range allosteric signaling. Together, these results identify specific interfacial residues as molecular gates that shape the conformational ensemble accessible to IGPS and show how interface reengineering can be used to rationally reprogram allosteric output. Significance StatementEnzymes often work like molecular switches: binding at one site can change activity at another distant site. How to predict or redesign this communication remains a major challenge. Using imidazole glycerol phosphate synthase (IGPS), we show that changing single amino acids at the interface between its two protein subunits can alter how the enzyme responds to regulation. One substitution shifts IGPS toward a response that changes both catalytic rate and substrate binding, whereas another weakens activation by disrupting communication across the interface. These findings identify interfacial residues that act as control points in an allosteric network and suggest a practical strategy for engineering enzymes with customized regulatory behavior.

biophysics↗

Dynamic and structural insights into allosteric regulation on MKP5 a dual-specificity phosphatase

Dual-specificity mitogen-activated protein kinase (MAPK) phosphatases (MKPs) directly dephosphorylate and inactivate the MAPKs. Although the catalytic mechanism of dephosphorylation of the MAPKs by the MKPs is established, a complete molecular picture of the regulatory interplay between the MAPKs and MKPs still remains to be fully explored. Here, we sought to define the molecular mechanism of MKP5 regulation through an allosteric site within its catalytic domain. We demonstrate using crystallographic and NMR spectroscopy approaches that residue Y435 is required to maintain the structural integrity of the allosteric pocket. Along with molecular dynamics simulations, these data provide insight into how changes in the allosteric pocket propagate conformational flexibility in the surrounding loops to reorganize catalytically crucial residues in the active site. Furthermore, Y435 contributes to the interaction with p38 MAPK and JNK, thereby promoting dephosphorylation. Collectively, these results highlight the role of Y435 in the allosteric site as a novel mode of MKP5 regulation by p38 MAPK and JNK.

biochemistry↗

Identification and Mechanistic Basis of non-ACE2 Blocking Neutralizing Antibodies from COVID-19 Patients with Deep RNA Sequencing and Molecular Dynamics Simulations

Variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) continue to cause disease and impair the effectiveness of treatments. The therapeutic potential of convergent neutralizing antibodies (NAbs) from fully recovered patients has been explored in several early stages of novel drugs. Here, we identified initially elicited NAbs (Ig Heavy, Ig lambda, Ig kappa) in response to COVID-19 infection in patients admitted to the intensive care unit at a single center with deep RNA sequencing (>100 million reads) of peripheral blood as a diagnostic tool for predicting the severity of the disease and as a means to pinpoint specific compensatory NAb treatments. Clinical data were prospectively collected at multiple time points during ICU admission, and amino acid sequences for the NAb CDR3 segments were identified. Patients who survived severe COVID-19 had significantly more of a Class 3 antibody (C135) to SARS-CoV-2 compared to non-survivors (16,315 reads vs 1,412 reads, p=0.02). In addition to highlighting the utility of RNA sequencing in revealing unique NAb profiles in COVID-19 patients with different outcomes, we provided a physical basis for our findings via atomistic modeling combined with molecular dynamics simulations. We established the interactions of the Class 3 NAb C135 with the SARS-CoV-2 spike protein, proposing a mechanistic basis for inhibition via multiple conformations that can effectively prevent ACE2 from binding to the spike protein, despite C135 not directly blocking the ACE2 binding motif. Overall, we demonstrate that deep RNA sequencing combined with structural modeling offers the new potential to identify and understand novel therapeutic(s) NAbs in individuals lacking certain immune responses due to their poor endogenous production. Our results suggest a possible window of opportunity for administration of such NAbs when their full sequence becomes available. A method involving rapid deep RNA sequencing of patients infected with SARS-CoV-2 or its variants at the earliest infection time could help to develop personalized treatments using the identified specific NAbs.

immunology↗